BriefGlance reported on a new study unveiled at ERS 2026 showing that Albus Health’s contactless, AI‑powered bedside device can reliably predict worsening asthma symptoms simply by listening for nocturnal cough. Researchers from Leiden University Medical Centre found that every five‑fold increase in nighttime cough was linked to a 1.5x higher chance of worse symptoms the next day, with the predictive window extending up to three days. With patients monitored for a median of 9.5 hours per night and near‑perfect adherence, the study highlights how passive, ambient monitoring can deliver objective, continuous data that transforms both clinical care and drug development.

The findings mark a major shift away from subjective patient reporting and toward proactive, personalised asthma management. By capturing high‑fidelity cough data without requiring patients to wear or do anything, Albus Health is helping clinicians intervene earlier, improving trial endpoints, and reducing patient burden, signalling a new era for digital biomarkers in respiratory disease.

Read the full article here.